Formulating with NMN / NAD+ Precursors: Key Research, Optimal Dosing, and Market Positioning

United Kingdom — 3 June 2026

The quest for longevity has always been a powerful commercial driver. Today, that quest is increasingly focused on NAD+ precursors such as Nicotinamide Mononucleotide (NMN), touted by some as the holy grail of anti-ageing. Yet, beneath the fervent marketing, how much of this promise is truly supported by robust science, and how much is speculative? Are we witnessing a genuine breakthrough for human health, or simply another costly ingredient chasing an elusive consumer dollar?

What the Clinical Evidence Actually Shows

The excitement surrounding NMN stems from its role in boosting cellular NAD+ levels, which decline with age and are implicated in various age-related conditions. Early preclinical studies, particularly in rodents, have shown promising results in improving metabolic health, muscle function, and even extending lifespan. Studies in aged mice have demonstrated that NMN supplementation could restore youthful NAD+ levels and improve vascular function. However, translating these findings to humans remains complex. Human trials are emerging, often with smaller cohorts and varying methodologies. Controlled trials have reported that daily NMN supplementation over several weeks to months improved muscle insulin sensitivity in overweight or obese postmenopausal women. Other trials have indicated that NMN increased NAD+ levels in the blood, though direct functional improvements were less pronounced. Limitations include the relatively short duration of most human trials, the use of surrogate markers for ageing, and potential conflicts of interest given the commercial investment in this space. In our view, while the preclinical data is compelling, caution is warranted. The dosage, delivery, and long-term efficacy in humans, particularly for healthy individuals, are still areas requiring much more rigorous, independent investigation.

The Formulation Reality

Formulating with NMN presents several practical challenges. Firstly, bioavailability is a key concern. NMN is susceptible to degradation in the acidic environment of the stomach. Enteric-coated capsules or liposomal delivery systems are often employed to enhance absorption, but these add significant cost and complexity. The stability of NMN itself is another factor; it is hygroscopic and can degrade when exposed to heat and moisture, necessitating careful storage and manufacturing conditions. Our formulation team's experience is that excipient interactions must be carefully considered. Common binders and fillers might compromise NMN's stability or bioavailability if not carefully selected. The optimal form of NMN — whether it's the free base or a salt — can also influence its performance. For example, some suppliers offer a 'stabilised' NMN, which typically implies a co-crystal or other protective matrix. Such considerations directly impact the cost of goods and the ultimate efficacy of the finished product. Shelf-life testing is paramount, often requiring accelerated stability studies over 12-24 months to ensure product integrity.

Market Position and Commercial Viability

The global NAD+ precursor market, inclusive of NMN and NR, has demonstrated substantial growth in recent years, fuelled by intense consumer interest in anti-ageing and wellness. However, the commercial landscape is highly competitive and marked by significant pricing pressures. Raw material costs for NMN remain elevated, varying considerably depending on purity and supplier. This translates to a high cost per dose for the consumer, with many finished products retailing at premium prices for a month's supply. Minimum Order Quantities (MOQs) for quality NMN can be substantial, posing a barrier for smaller brands. For manufacturers, achieving healthy margins requires careful supply chain management and a clear value proposition. The NMN market represents significant opportunity, but brands need robust clinical differentiation and a compelling narrative beyond mere hype to justify the premium price point and ensure long-term viability. Generic, unproven NMN products, often imported without stringent quality controls, further complicate the market, eroding trust and potential margins for reputable players.

What This Means for United States

In the United States, the regulatory status of NMN has been a point of contention. While initially marketed as a dietary supplement, the FDA issued a notice in 2022 stating that NMN cannot be marketed as such because it has been authorised for investigation as a new drug. This ruling has created significant uncertainty and challenges for supplement brands. Consumer demand, however, remains robust, driven by extensive online discourse and celebrity endorsements. The competitive landscape is fierce, with both established supplement companies and new entrants vying for market share. Brands currently selling NMN are operating in a grey area, with the future regulatory pathway unclear. This environment necessitates a cautious approach, prioritising scientific integrity and transparent communication with consumers. The market will likely continue to bifurcate, with some brands pushing boundaries and others adopting a 'wait and see' approach.

The Bottom Line for Formulators

Formulators considering NMN must weigh the substantial market potential against significant clinical, regulatory, and cost challenges. Investment is only advisable for brands prepared to commit to rigorous quality control, invest in bioavailability-enhancing formulations, and navigate an evolving regulatory environment. Without clear, robust human efficacy data for specific health claims, NMN remains a high-risk, high-reward ingredient. Focus on transparent sourcing and educating consumers on the current scientific understanding, rather than relying on unsubstantiated anti-ageing claims, will be critical for any brand hoping to succeed in this complex category.